Anteris Technologies Global Corp.
Reads like this one publish minutes after the filing lands on EDGAR. Get them as JSON over the API or inside your AI agent over MCP.
L1 Capital sold 7,800 shares of Anteris Technologies (AVR) at $8.83 each on 2026-08-28, reducing its indirect stake to 4,803,541 shares. It retains 5,359,470 CHESS Depository Interests and 1,333,334 warrants, both held indirectly. The warrants expire in 2030 with an exercise price of AUD 11.50.
L1 Capital Pty Ltd sold 627,659 indirectly-held shares of Anteris Technologies Global Corp. (AVR) at an average of $9.22 ($9.10–$9.30, $5.79M total) across 2 trades over 2026-08-10 to 2026-08-11.
Anteris Technologies (ASX:AVR, NASDAQ:AVR) said it advanced its pivotal PARADIGM Trial in the June quarter, enrolling and treating its first US patients after CMS Medicare reimbursement eligibility for qualifying procedures. Recruitment expanded to the US, Denmark and the Netherlands, with Canada and France receiving regulatory clearance. The trial targets about 1,000 patients. Net operating cash outflows were US$20.8m.
Over the past 7 days, alphai's AI scored 1 news story mentioning AVR (Anteris Technologies Global Corp.). Coverage has been balanced: 0 bullish, 1 neutral, and 0 bearish.
Recent AVR coverage spans insider activity, financial news and technology.
In the last 30 days, AVR insiders filed 7 SEC Form 4 transactions — no purchases and 7 sales ($15.2M). The most active reporter was L1 Capital Pty Ltd with 7 filings.
A reported 10% owner trim signals mild near-term overhang risk, but the position remains large and includes long-dated warrants.
The filing discloses a sizable insider-related indirect sale, which can pressure near-term sentiment but does not change fundamentals by itself.
CMS reimbursement eligibility and US patient start reduce key execution risk for the pivotal PARADIGM trial, supporting a more constructive path to enrollment momentum.
CMS reimbursement eligibility and the start of U.S. enrollment are near-term execution catalysts for the PARADIGM Trial, supporting commercialization optionality.
The filing provides updated quarterly and year-to-date financial condition, but no new clinical, regulatory, or commercial milestone is disclosed in the excerpt.
alphai scores every news story that mentions AVR with an AI model for sentiment and relevance, and aggregates insider trades from Anteris Technologies Global Corp.'s SEC EDGAR Form 4 filings. Figures refresh continuously.
L1 Capital sold 7,800 shares of Anteris Technologies (AVR) at $8.83 each on 2026-08-28, reducing its indirect stake to 4,803,541 shares. It retains 5,359,470 CHESS Depository Interests and 1,333,334 warrants, both held indirectly. The warrants expire in 2030 with an exercise price of AUD 11.50.
3 min readL1 Capital Pty Ltd sold 627,659 indirectly-held shares of Anteris Technologies Global Corp. (AVR) at an average of $9.22 ($9.10–$9.30, $5.79M total) across 2 trades over 2026-08-10 to 2026-08-11.
2 min readAnteris Technologies (ASX:AVR, NASDAQ:AVR) said it advanced its pivotal PARADIGM Trial in the June quarter, enrolling and treating its first US patients after CMS Medicare reimbursement eligibility for qualifying procedures. Recruitment expanded to the US, Denmark and the Netherlands, with Canada and France receiving regulatory clearance. The trial targets about 1,000 patients. Net operating cash outflows were US$20.8m.
4 min readAnteris Technologies Global Corp. (NASDAQ: AVR, ASX: AVR) reported Q2 2026 results for the quarter ended June 30, 2026. It said CMS granted Medicare reimbursement eligibility for the PARADIGM Trial, U.S. recruitment began with first patients treated in May 2026, and the trial expanded to multiple regions. Net operating cash outflows were $20.8M; R&D expenses were $23.4M.
6 min readAnteris Technologies Global Corp. (AVR) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 Anteris Technologies Announces Results for the Second Quarter of 2026 MINNEAPOLIS, United States and BRISBANE, Australia August 12, 2026 (AEST) Anteris Technologies Global Corp. (“Anteris” or the “Company”) (NASDAQ: AVR, ASX: AVR) a global healthcare company committe
4 min readL1 Capital Pty Ltd sold 174,721 indirectly-held shares of Anteris Technologies Global Corp. (AVR) at $8.10 ($1.42M total) on 2026-08-06.
2 min readL1 Capital Pty Ltd sold 495,189 indirectly-held shares of Anteris Technologies Global Corp. (AVR) at an average of $8.30 ($8.23–$8.30, $4.11M total) across 2 trades over 2026-08-04 to 2026-08-05.
2 min readL1 Capital Pty Ltd sold 524,404 indirectly-held shares of Anteris Technologies Global Corp. (AVR) at an average of $8.10 ($8.10–$8.15, $4.25M total) across 2 trades over 2026-07-31 to 2026-08-03.
2 min readL1 Capital Pty Ltd sold 714,138 indirectly-held shares of Anteris Technologies Global Corp. (AVR) at an average of $8.17 ($8.04–$8.20, $5.83M total) across 2 trades over 2026-07-29 to 2026-07-30.
2 min readAustralia’s ASX 200 ended near flat, up 0.10% after a 1.03% session high. Materials led early, supported by higher copper and iron ore, with BHP, Rio Tinto and Newmont rising, while Fortescue fell 2.12% on cost and capex concerns. The piece also covers ASX listings and updates for ARU, MHJ, CMA, and others.
7 min read
